Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
about
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxA Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVAMerozoite surface proteins in red blood cell invasion, immunity and vaccines against malariaThe evolution of poxvirus vaccinesCD4(+) T Cell Priming as Biomarker to Study Immune Response to Preventive Vaccines4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaquesPhenotypic characterization of Plasmodium berghei responsive CD8+ T cells after immunization with live sporozoites under chloroquine coverFusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates.A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.Distinct patterns of diversity, population structure and evolution in the AMA1 genes of sympatric Plasmodium falciparum and Plasmodium vivax populations of Papua New Guinea from an area of similarly high transmissionNew gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route.The influence of delivery vectors on HIV vaccine efficacySterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopesAssessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureA phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malariaCombining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsRegression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe.A proposal to use iterative, small clinical trials to optimize therapeutic HIV vaccine immunogens to launch therapeutic HIV vaccine development.The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy AdultsRecombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malariaDifferential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in miceA vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.Tailoring a Combination Preerythrocytic Malaria VaccineComparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.
P2860
Q24273364-A01583C0-AF81-4093-AD66-616AB8BA119CQ24289279-E423727F-207E-4F5C-89FD-27A69FE36443Q26772878-62B80889-B9D6-4911-9355-50B1EDF5D15AQ26995905-5193795F-F481-49E4-913F-7F0D36D2147EQ27014949-DBCEE0EF-02EA-4F5C-8238-86BC3C4340F5Q27314155-01CA8040-535B-41E1-9F56-6832E1E3F88FQ33558847-E494218F-01C1-43D3-A59A-6483B0418E27Q33586992-013CD1D2-B823-43B2-8F12-263DB133475CQ33724960-C9CE0334-9E34-430B-814A-6EB6161F6666Q33798074-AB01750F-EEB3-4EBE-AE9D-0FBDE372A9D8Q33859217-83963AF1-D116-45C8-872E-C9EED41A105BQ33868760-4A496C6B-1048-4E31-93E1-021290063241Q33875160-1F76D24A-C71E-449B-87AF-962B6D19D133Q34072792-C16E134D-3FC2-4645-865A-253BA66A018AQ34077543-F71E5D47-E090-4F03-A1F5-6BA73251E236Q34165879-23B9F1EA-6F8D-43C3-B2CE-56998548F5E4Q34257253-60DB95F5-6E4F-454B-A7CA-522FA634D75AQ34369139-E80D8A38-68A3-4A71-8744-7D14C33F9B71Q34416263-DFC3F2C0-425C-483F-9950-4D3D2C28FFE2Q34469817-DE7630FD-DEFD-4984-8486-7F47F3BCA1A2Q34600955-231181C8-E10D-4ECA-AA06-FEC49D7BEFEEQ34606356-DEFD3945-3CF9-4D2D-863C-479149A1EDFFQ34634002-4C197F83-D6D8-427E-857A-A0A0C709F681Q34729962-2C14BC7C-6EB1-46BD-8C58-69B36065F124Q34734075-1FDEE6B6-EFAF-4A57-8648-ED2CBCACD107Q34792326-F56148A1-234F-45F5-88C3-618DFDD83B99Q34869364-76A2E99F-C46F-453A-B4D0-6A5501124AAFQ35091556-0E145AA2-C53B-4BEA-9570-E554A900A7A7Q35163318-E7472A31-FFB5-4D20-8B38-BFFFC3A2A1FEQ35344875-4B5A1787-2713-4A00-A8E3-FB384EF3230DQ35718341-75E80431-7E0D-48D0-BFB0-4CDD00A0A0E0Q35830513-FE3E6292-C93F-4B21-A373-39E9748E1D0EQ36043731-D2357D92-71FC-4B39-8E1E-8F886AD28960Q36064542-27D907ED-FA1B-4F35-8A99-AC55D37087A4Q36291682-D805B62C-0CFB-4709-8B45-A7FFF30D75D0Q36391900-68D88FB0-2526-4EA6-B117-B6A3E8A74431Q36394177-6804F552-37AA-413E-B3CC-79A9AA914845Q36460499-E6251FE6-F7C1-4385-8C5C-E4B68FC40FE3Q36631331-347C9144-A894-4386-9831-F48B494B99EAQ36674446-DA008E90-BE4C-4460-8EE0-31899DCF105E
P2860
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase Ia clinical evaluation o ...... ChAd63 and MVA vaccine vectors
@ast
Phase Ia clinical evaluation o ...... ChAd63 and MVA vaccine vectors
@en
Phase Ia clinical evaluation o ...... ChAd63 and MVA vaccine vectors
@nl
type
label
Phase Ia clinical evaluation o ...... ChAd63 and MVA vaccine vectors
@ast
Phase Ia clinical evaluation o ...... ChAd63 and MVA vaccine vectors
@en
Phase Ia clinical evaluation o ...... ChAd63 and MVA vaccine vectors
@nl
prefLabel
Phase Ia clinical evaluation o ...... ChAd63 and MVA vaccine vectors
@ast
Phase Ia clinical evaluation o ...... ChAd63 and MVA vaccine vectors
@en
Phase Ia clinical evaluation o ...... ChAd63 and MVA vaccine vectors
@nl
P2093
P2860
P50
P3181
P1433
P1476
Phase Ia clinical evaluation o ...... ChAd63 and MVA vaccine vectors
@en
P2093
Alfredo Nicosia
Alison M Lawrie
Christopher J A Duncan
Eleanor Berrie
Geraldine A O'Hara
Ian D Poulton
Katherine Gantlett
Matthew D J Dicks
Riccardo Cortese
Sarah Moyle
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0031208
P407
P50
P577
2012-01-01T00:00:00Z